European Commission grants approval of shorter duration of glecaprevir/pibrentasvir (Maviret) for treatment-naïve genotype 3 hepatitis C virus (HCV) patients with compensated cirrhosis
The EC has approved a shorter duration use for glecaprevir/pibrentasvir (Maviret) from 12 to 8 weeks in treatment-naïve, compensated cirrhotic, chronic HCV patients with genotype (GT)3 infection.
Source:
Biospace Inc.